monovalent H1N1 influenza virus vaccine

The monovalent H1N1 influenza virus vaccine, most notably known by the brand name **Focetria**, is an inactivated subunit vaccine developed by **Novartis** to prevent infection from the 2009 pandemic H1N1 influenza A virus. It contains purified surface antigens, specifically hemagglutinin (HA) and neuraminidase (NA), derived from the A/California/7/2009 (H1N1)v-like strain (prepared from the reassortant virus NYMC X-179A). The vaccine is produced in embryonated chicken eggs and is typically formulated with the **MF59** adjuvant, a squalene-based oil-in-water emulsion designed to enhance the magnitude and breadth of the immune response, allowing for dose-sparing. Focetria was granted marketing authorization by the European Medicines Agency (EMA) during the 2009 pandemic and was evaluated in various populations, including children and the elderly, demonstrating high immunogenicity and a manageable safety profile. While Novartis was the original developer, its vaccine business was later acquired by **CSL (Seqirus)** and **GSK**.

Brand names

Focetria

Other names

pandemic influenza vaccine (H1N1) (surface antigen, inactivated, adjuvanted)A/H1N1 MF59-adjuvanted vaccineH1N1v vaccineH-1N1v vaccineH 1N1v vaccineA/H1N1 influenza subunit vaccine